🇺🇸 FDA
Pipeline program

anti-BCMA CAR-T

IIT2022064

Phase 2 mab active

Quick answer

anti-BCMA CAR-T for Plasma Cell Leukemia is a Phase 2 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
Plasma Cell Leukemia
Phase
Phase 2
Modality
mab
Status
active

Clinical trials